Back to News
Market Impact: 0.2
Theriva Biologics Sells Enzyme Portfolio; Shifts Focus To VCN-01; Stock Up
Source: Nasdaq
M&A & RestructuringHealthcare & BiotechCompany Fundamentals
Theriva Biologics announced the sale of its antibiotic-degrading enzyme portfolio—including SYN-004 (ribaxamase), SYN-007 and SYN-006—to Toronto-based Biossil Labs. The available article text provides no sale price, other terms or expected financial impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
TOVX0.50
More News
- Binance co-CEO Richard Teng says hackers used fake job interviews, AI tool to steal $6.3 billion in crypto 108511116
- AMD stock jumps 7% on earnings as data center revenue nearly doubles
- Marvell-Lumentum Deal Puts Optical Networking at the Center of the AI Boom
- Marvell Technology could plunge on latest multibillion-dollar acquisition
- Disney Plans Thousands of Layoffs Companywide
- AMD rides data center riches to ‘largest and most profitable’ quarter in history